MedTrace Logo

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT02228850 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2016-03-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).

Conditions

  • Raynaud's Phenomenon Secondary to Systemic Sclerosis

Interventions

DRUG

Alprostadil

OTHER

Placebo

Sponsors & Collaborators

  • NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

    lead INDUSTRY

Principal Investigators

  • Barbara Troupin, MD, MBA · NEXMED (U.S.A.), Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-06-30
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228850 on ClinicalTrials.gov